SHARE PURCHASE AGREEMENTShare Purchase Agreement • December 2nd, 2019 • Xenon Pharmaceuticals Inc. • Pharmaceutical preparations • New York
This Share Purchase Agreement (this “Agreement”), is made as of December 2, 2019 (the “Signing Date”), by and between Neurocrine Biosciences, Inc. (the “Investor”), a Delaware corporation, and Xenon Pharmaceuticals Inc. (the “Company”), a Canadian corporation.
License and Collaboration AgreementLicense and Collaboration Agreement • December 2nd, 2019 • Xenon Pharmaceuticals Inc. • Pharmaceutical preparations • New York
This License and Collaboration Agreement (this “Agreement”) is made as of December 2, 2019 (the “Effective Date”), by and between Xenon Pharmaceuticals Inc., a Canadian corporation (“Xenon”), having its principal office at 200-3650 Gilmore Way, Burnaby, BC V5G 4W8, Canada, and Neurocrine Biosciences, Inc., a Delaware corporation (“Neurocrine”), having its principal office at 12780 El Camino Real, San Diego, California 92130, U.S. Neurocrine and Xenon are referred to in this Agreement individually as a “Party” and collectively as the “Parties”.
